FDA Looms Large As Bayer Surrenders One A Day Selenium Prostate Claims
This article was originally published in The Tan Sheet
Bayer seems to be heeding FDA's message that the administration will not tolerate playing fast and loose with health claims
You may also be interested in...
A court decision obligating FDA to reconsider a slate of qualified health claims for selenium could compel the agency to allow more QHCs for dietary supplements
FDA's rejection of certain qualified health claims linking selenium to cancer prevention violates a federal court ruling that mandates a First Amendment standard for reviewing QHCs, Jonathan Emord asserts. The Clifton, Va.-based attorney filed a 1complaint July 30 in the U.S. District Court for the District of Columbia on behalf of the Alliance for Natural Health U.S., the Coalition to End FDA and FTC Censorship, which Emord founded, and supplement businesspersons Durk Pearson and Sandy Shaw. FDA recently approved a number of narrowly qualified, essentially unusable QHCs for selenium in response to an Emord citizen petition (2"The Tan Sheet" June 29, 2009). "FDA has denied consumers accurate representations of nutrition science," the complaint states
The Center for Science in the Public Interest says FDA should "flex its muscles" and make an example of Bayer's selenium claims for One A Day Men's multivitamins, just as it did with General Mills' heart health claims for Cheerios